Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 35 clinical trials
Myeloma-Developing Regimens Using Genomics (MyDRUG)

uncontrolled cell growth and cancer. Patients with a greater than 25% mutation to any of the following genes; CDKN2C, FGFR3, KRAS, NRAS, BRAF V600E, IDH2 or T(11;14) can be enrolled to one of the treatment

  • 18 views
  • 16 Sep, 2021
  • 14 locations
Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations

This is an open-label, multi-center Phase 1 study of LY3410738, an oral, covalent IDH inhibitor, in patients with IDH1 and/or IDH2-mutant advanced hematologic malignancies who have received

IDH2
blast cells
hematologic malignancy
  • 0 views
  • 16 Sep, 2021
  • 47 locations
A Study of Ivosidenib or Enasidenib in Combination With Induction Therapy and Consolidation Therapy Followed by Maintenance Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myedysplastic Syndrome EB2 With an IDH1 or IDH2 Mutation Respectively Eligible for Intensive Chemotherapy

cells (blasts) have developed an error in the genetic material (DNA). This error is called an IDH1 mutation or an IDH2 mutation (a mutation is a change in the DNA), which leads to changes in specific

consolidation therapy
cancer
blast cells
enasidenib
neoadjuvant therapy
  • 38 views
  • 10 Sep, 2021
  • 177 locations
Study of Vorasidenib (AG-881) in Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation (INDIGO)

2 glioma with an IDH1 or IDH2 mutation who have undergone surgery as their only treatment. Participants will be required to have central confirmation of IDH mutation status prior to randomization

  • 2 views
  • 04 Jul, 2021
  • 71 locations
SEL24/MEN1703 in Patients With Acute Myeloid Leukemia

The purpose of the clinical trial is to identify the maximum tolerated dose of SEL24/MEN1703 and to further investigate its safety profile in patients with Acute Myeloid Leukemia.

IDH2
refractory acute myeloid leukemia (aml)
  • 71 views
  • 09 Sep, 2021
  • 18 locations
Veliparib Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed Malignant Glioma Without H3 K27M or BRAFV600 Mutations

This phase II trial studies how well veliparib, radiation therapy, and temozolomide work in treating patients with newly diagnosed malignant glioma without H3 K27M or BRAFV600 mutations. Poly adenosine diphosphate (ADP) ribose polymerases (PARPs) are proteins that help repair DNA mutations. PARP inhibitors, such as veliparib, can keep PARP from …

blood transfusion
MRI
cancer
astrocytoma, anaplastic
anaplastic astrocytoma
  • 403 views
  • 26 Sep, 2021
  • 112 locations
IDH2 (AG 221) Inhibitor in Patients With IDH2 Mutated Myelodysplastic Syndrome

patients with MDS (Myelodysplastic Syndrome) and mutated IDH2 patients will be treated with AG221 (IDH2 inhibitor)

blood transfusion
azacitidine
granulocyte colony stimulating factor
cancer
blast cells
  • 4 views
  • 27 Jan, 2021
  • 30 locations
IDH2-Post-Allo-Trial for Patients With IDH2-mut Myeloid Neoplasms After Allo-SCT

prophylactic consolidation in patients with IDH2-mutated MDS, CMML and AML in remission after allo-SCT and as salvage therapy in patients with IDH2-mutated MDS, CMML and AML who have relapsed after allo-SCT

cancer
enasidenib
graft versus host disease
chronic myelomonocytic leukemia
hydroxyurea
  • 0 views
  • 26 Jan, 2021
  • 1 location
Testing Olaparib and AZD6738 in IDH1 and IDH2 Mutant Tumors

This phase II trial studies how well olaparib and ceralasertib (AZD6738) work in treating patients with IDH mutant cholangiocarcinoma or solid tumors. Cancer is caused by changes (mutations) to genes that control the way cells function. Laboratory studies have shown that olaparib and AZD6738 can shrink IDH mutant tumors or …

blood transfusion
tumor cells
olaparib
cancer
neutrophil count
  • 5 views
  • 06 Sep, 2021
  • 11 locations
Study of Enasidenib and Venetoclax in IDH2-Mutated Blood Cancers

The purpose of this research study is to see how safe and tolerable, and to find the highest or best dose, of an investigational combination of drugs called enasidenib and venetoclax, in patients with relapsed (the cancer has come back) or refractory (the cancer does not respond or have stopped …

cancer
venetoclax
enasidenib
refractory acute myeloid leukemia (aml)
myelodysplastic syndromes
  • 0 views
  • 25 May, 2021
  • 2 locations